INTRODUCTION AND OBJECTIVES:
We reported that tumor invades peripelvic fat or periureteral fat (pT3b) had worse prognosis than tumor invades renal parenchyma (pT3a) 1 . We evaluated the disease recurrence and cancer specific survival of patients with pT3b urothelial carcinoma of the upper urinary tract who received adjuvant treatment. Reference 1. Park, J., et al., Peripelvic/periureteral fat invasion is independently associated with worse prognosis in pT3 upper tract urothelial carcinoma. World J Urol, 2014. 32(1): p. 157-63.
METHODS: The data from a total of the 128 pT3b patients after radical nephroureterectomy were analyzed. The patients were divided into 4groups; 60 without adjuvant therapy (Group 1), 22 with adjuvant radiotherapy (Group 2), 27 with adjuvant chemotherapy (Group 3) and 19 with adjuvant radiotherapy plus adjuvant chemotherapy (Group 4).
Recurrence-free survival and cancer specific survival rates were compared among these groups.
RESULTS: The median follow-up duration was 43.7 months. The patients who received adjuvant radiotherapy (Group 2 and 4) were more likely to have high pathologic grade (p¼0.036) and more frequent positive surgical margin (p¼0.010), but were no differences by gender, age, tumor location, status of lymphovascular invasion. 5-year recurrence-free survival rates of group 1, group 2, group 3 and group 4 were 31.3%, 66.3%, 26.1% and 57.9%, respectively. The patients who received adjuvant radiotherapy (Group 2 and 4) showed significantly higher recurrence free survival than those who did not. Low recurrence rates after adjuvant radiotherapy may be due to decreased local recurrence (HR 0.129, p¼0.005). 5-year cancer specific survival rates in group 1, group 2, group 3 and group 4 were 51.6%, 50.6%, 50.6% and 72.7%, respectively. Higher cancer specific survival was noted in group 4, but didn 0 t reach statistical significance (p¼0.119).
CONCLUSIONS: The Adjuvant radiotherapy in pT3b patients significantly reduced disease recurrence. Adjuvant radiotherapy plus chemotherapy seem to increase the cancer specific survival. The adjuvant radiotherapy plus chemotherapy should be considered in patients with pT3bN0/Nx. is histologically similar to urothelial carcinoma of the bladder, but frequently associated with high grade (HG) invasive disease at diagnosis, resulting in poor outcomes. Although Level I evidence supports the use of cisplatin based neoadjuvant chemotherapy (NAC) for patients with muscle invasive bladder cancer, there is currently no level 1 data supporting the use of peri-operative chemotherapy for patients with HG UTUC. Given the inability to accurately stage UTUC, some speculate that NAC for patients undergoing nephroureterectomy (NU) for HG UTUC may improve outcomes, considering their limited eligibility for adjuvant chemotherapy due to renal impairment. Our study objective was to evaluate the impact of NAC in patients who underwent NU for pathologically proven HG UTUC.
Source of
METHODS: A retrospective review was conducted of patients with HG UTUC at our institution from 2012 to 2016 who underwent NU. As per department protocol, all patients scheduled for NU with pre-op estimated glomerular filtration rate (eGFR) > 45 mL/min per 1.73 m2 were referred for evaluation of NAC. Clinical and pathologic response rates were noted, with pre-and post-operative kidney function defined by eGFR.
RESULTS: A total of 58 patients met inclusion criteria, with a median age was 75 years (range: 35-92) and a pre-op and post-op eGFR of 54.45 and 47.6 mL/min per 1.73 m2 respectively. 26 patients were considered eligible for NAC, of which 18 (69%) received NAC. The rate of utilization increased over time (Figure 1 ). 13/18 (72%) demonstrated a clinical response including 6 (33%) with a complete clinical response. Final pathology demonstrated pT0N0 in 2 patients (11%) and pTisN0 in 2 patients (11%). No patients suffered a delay or were deemed ineligible for surgery due to NAC.
CONCLUSIONS: Cisplatin based NAC demonstrated a clinical response rate in the majority of patients with HG UTUC without compromising definitive surgical treatment. Since NU significantly reduces kidney function and eligibility for cisplatin based chemotherapy, patients with HG UTUC may be considered candidates for NAC. Longer follow-up data is needed to further assess the impact of NAC on survival rates. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e949
